Arcadia Biosciences, Inc. (NASDAQ: RKDA) filed a 424B3 prospectus supplement registering 11,922,333 shares for resale — approximately 5.5 times the company's 2,181,715 shares currently outstanding. The shares are tied to a private placement with a single institutional holder, Armistice Capital Master Fund Ltd.

Structure of the Deal

The registered shares break down into several tranches, each with a fixed exercise price:

• Pre-funded warrants exercisable at $0.0001 per share, which function as near-free conversion into common stock.
• Investment options with a fixed strike price of $0.91.
• Placement-agent warrants exercisable at $1.2875.

All conversion and exercise prices are fixed. The filing contains no variable-rate or VWAP-linked pricing mechanisms, and the agreement includes a one-year prohibition on Variable Rate Transactions. That prohibition contractually blocks the company from issuing securities with floating or adjustable conversion prices for the restricted period, limiting one common path to further structural dilution.

Dilution Mechanics

The pre-funded warrants deserve particular attention. At an exercise price of $0.0001, they are economically equivalent to outstanding shares — the holder has already paid substantially all of the consideration, and conversion is essentially costless. Once exercised, these shares would immediately enter the tradable float.

The investment options at $0.91 and placement-agent warrants at $1.2875 carry more meaningful exercise prices, but both sit below or near recent trading levels, which means they could be exercised without requiring significant share-price appreciation.

Because all tranches are registered for resale under this prospectus, the holder is not subject to Rule 144 volume restrictions when liquidating. The entire 11.9 million shares can, in principle, be sold into the open market at the holder's discretion once the registration statement is effective.

Scale Relative to Float

The ratio of registered shares to outstanding shares — roughly 547% — is unusually large even by micro-cap standards. Arcadia's post-reverse-split float is small, which amplifies the structural weight of any single block of registered shares. The concentration of this overhang in a single institutional holder means that the pace and timing of any selling activity would be determined by one counterparty's decisions.

What the Filing Does Not Contain

Notably absent from the deal terms are several features common in deeply dilutive micro-cap financings: there is no death-spiral convertible, no VWAP-based repricing, and no equity line or at-the-market facility embedded in this particular transaction. The fixed-price structure means the conversion economics do not worsen as the stock price declines.

The one-year Variable Rate Transaction prohibition expires twelve months from the closing date of the offering, after which the company would regain the ability to enter into floating-price financings.